ST PHARM CO., LTD. Logo

ST PHARM CO., LTD.

A global CDMO specializing in APIs and RNA therapeutics for the gene therapy market.

237690 | KO

Overview

Corporate Details

ISIN(s):
N/A
LEI:
Country:
South Korea
Address:
경기도 시흥시 협력로 231(정왕동, 시화공단 1나 802호), 시흥시
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

ST Pharm Co., Ltd. is a global Contract Development and Manufacturing Organization (CDMO) specializing in Active Pharmaceutical Ingredients (APIs) for the gene therapy market. The company is a key manufacturer of RNA-based therapeutics, with technology-driven services spanning from oligonucleotides to xRNA and mRNA. ST Pharm provides comprehensive, cGMP-compliant custom manufacturing solutions for both novel and generic drugs. With over 30 years of experience, the company supports its global partners through the entire development lifecycle, from research and development to commercial-scale production, quality control, and regulatory affairs.

This is a Fraction of the Available Data.

You're viewing a limited, static snapshot. Professionals use our API to get real-time, AI-ready data for ST PHARM CO., LTD. and 9,000+ other companies.

Stop analyzing yesterday's news. Start building a real-time advantage.

Request Enterprise API Access

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-09-10 00:00
Report Publication Announcement
기업설명회(IR)개최
Korean 8.3 KB
2025-09-08 00:00
Share Issue/Capital Change
전환청구권행사
Korean 10.8 KB
2025-08-14 00:00
Annual Report
[기재정정]사업보고서 (2024.12)
Korean 3.4 MB
2025-08-14 00:00
Interim Report
반기보고서 (2025.06)
Korean 2.6 MB
2025-08-13 00:00
Report Publication Announcement
기업설명회(IR)개최
Korean 7.0 KB
2025-07-25 00:00
Major Shareholding Notification
주식등의대량보유상황보고서(일반)
Korean 119.1 KB
2025-07-24 00:00
Earnings Release
연결재무제표기준영업(잠정)실적(공정공시)
Korean 16.8 KB
2025-07-24 00:00
Report Publication Announcement
기업설명회(IR)개최
Korean 7.0 KB
2025-07-18 00:00
Report Publication Announcement
결산실적공시예고
Korean 3.8 KB
2025-07-18 00:00
Report Publication Announcement
기업설명회(IR)개최
Korean 6.8 KB

Automate Your Workflow. Get a real-time feed of all ST PHARM CO., LTD. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

No Financial Data Available

Standardized financial statements for the selected period are not yet available.

Need More History? Access decades of standardized financials for ST PHARM CO., LTD. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Company Country Ticker View
SK Bioscience Co.,Ltd Logo
A global biotech firm developing vaccines for diseases like COVID-19, influenza, and shingles.
South Korea 302440
SoftOx Solutions AS Logo
Develops non-toxic, AMR-safe antimicrobials for wound care, disinfection & airway infections.
Norway SOFTX
Solasia Pharma K.K. Logo
In-licenses and commercializes oncology treatments and supportive care products in Asia.
Japan 4597
Sopharma AD Logo
Develops, manufactures, and distributes pharmaceuticals and generics in Bulgaria and regional markets.
Bulgaria SFA
Spago Nanomedical AB Logo
Developing nanomedicines for precise cancer diagnosis and targeted radionuclide therapy.
Sweden SPAGO
Spexis AG Logo
Clinical-stage biopharma developing macrocyclic therapeutics for rare diseases and oncology.
Switzerland SPEX
Sprint Bioscience Logo
Develops & out-licenses preclinical oncology drugs for difficult-to-treat cancers.
Sweden SPRINT
STADA Arzneimittel AG Logo
A leading European manufacturer of generics, consumer healthcare, and specialty pharmaceuticals.
Germany SAZ
Stayble Therapeutics AB Logo
Develops an injectable drug for lumbar disc herniation pain as an alternative to surgery.
Sweden STABL
STCUBE Logo
Develops first-in-class immunotherapies targeting BTN1A1 for treatment-resistant cancers.
South Korea 052020

Talk to a Data Expert

Have a question? We'll get back to you promptly.